Here, we identified a 15 lncRNAs signature in advanced melanoma by weighted gene co-expression network analysis (WGCNA) and logistic least absolute shrinkage and selection operator (LASSO) in the training cohort (PRJNA356761) and validated it in the validation cohort (PRJEB23709) to determine and predict the response of melanoma patients receiving anti-PD-1 monotherapy. This evidence concerns the gene PDCD1 and melanoma.